ES2191260T3 - Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos. - Google Patents
Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos.Info
- Publication number
- ES2191260T3 ES2191260T3 ES98310580T ES98310580T ES2191260T3 ES 2191260 T3 ES2191260 T3 ES 2191260T3 ES 98310580 T ES98310580 T ES 98310580T ES 98310580 T ES98310580 T ES 98310580T ES 2191260 T3 ES2191260 T3 ES 2191260T3
- Authority
- ES
- Spain
- Prior art keywords
- imidazolidin
- ona
- derivatives
- useful
- target agents
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Lifetime
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
- C07D231/02—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings
- C07D231/10—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D231/12—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/454—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. pimozide, domperidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/56—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/54—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
- C07D233/66—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D233/70—One oxygen atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D249/00—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms
- C07D249/02—Heterocyclic compounds containing five-membered rings having three nitrogen atoms as the only ring hetero atoms not condensed with other rings
- C07D249/08—1,2,4-Triazoles; Hydrogenated 1,2,4-triazoles
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Oncology (AREA)
- Dermatology (AREA)
- Urology & Nephrology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Abstract
LA PRESENTE INVENCION SE REFIERE A COMPUESTOS REPRESENTADOS POR LA FORMULA 1: Y A SALES FARMACEUTICAMENTE ACEPTABLES Y A SOLVATOS DE LOS MISMOS, DONDE Z, R, R 3 Y R 4 REPRESENTAN LO QUE SE DEFINE EN LA DESCRIPCION. LA INVENCION TAMBIEN SE REFIERE A COMPOSICIONES FARMACEUTICAS QUE CONTIENEN DICHOS COMPUESTOS DE FORMULA 1 Y A PROCEDIMIENTOS DE INHIBICION DEL CRECIMIENTO CELULAR ANORMAL, INCLUYENDO CANCERES, EN UN MAMIFERO, MEDIANTE LA ADMINISTRACION DE DICHOS COMPUESTOS A DICHO MAMIFERO.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US7001097P | 1997-12-30 | 1997-12-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
ES2191260T3 true ES2191260T3 (es) | 2003-09-01 |
Family
ID=22092561
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ES98310580T Expired - Lifetime ES2191260T3 (es) | 1997-12-30 | 1998-12-22 | Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos. |
Country Status (10)
Country | Link |
---|---|
US (1) | US6080769A (es) |
EP (1) | EP0928788B1 (es) |
JP (1) | JPH11236333A (es) |
AT (1) | ATE232520T1 (es) |
BR (1) | BR9805734A (es) |
CA (1) | CA2257016C (es) |
DE (1) | DE69811329T2 (es) |
DK (1) | DK0928788T3 (es) |
ES (1) | ES2191260T3 (es) |
PT (1) | PT928788E (es) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2000025789A1 (en) * | 1998-10-29 | 2000-05-11 | Merck & Co., Inc. | A method of treating endometriosis |
EP1006113A1 (en) | 1998-12-02 | 2000-06-07 | Pfizer Products Inc. | Derivatives of 2-(2-oxo-ethylidene)-imidazolidin-4-one and their use to inhibit abnormal cell growth |
AU2477400A (en) | 1998-12-08 | 2000-06-26 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
WO2000034239A2 (en) | 1998-12-08 | 2000-06-15 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferase |
PT1585743E (pt) * | 2002-12-19 | 2007-07-12 | Pfizer | Compostos de 2- (1h-indazol-6-ilamin)-benzamida como inibidores de proteína-cinases úteis para o tratamento de doenças aftálmicas. |
JP2007530654A (ja) * | 2004-03-30 | 2007-11-01 | ファイザー・プロダクツ・インク | シグナル伝達阻害剤の組合せ |
DK1784396T3 (da) * | 2004-08-26 | 2011-02-14 | Pfizer | Pyrazol-substituerede aminoheteroaryl-forbindelser som proteinkinase-inhibitorer |
BRPI0513915A (pt) * | 2004-08-26 | 2008-05-20 | Pfizer | compostos aminoeteroarila enantiomericamente puros como inibidores de proteìna quinase |
WO2006021886A1 (en) * | 2004-08-26 | 2006-03-02 | Pfizer Inc. | Aminoheteroaryl compounds as protein tyrosine kinase inhibitors |
US20060107555A1 (en) * | 2004-11-09 | 2006-05-25 | Curtis Marc D | Universal snow plow adapter |
PL2960253T3 (pl) | 2005-09-07 | 2018-11-30 | Amgen Fremont Inc. | Ludzkie przeciwciała monoklonalne przeciwko kinazie podobnej do receptora aktywiny-1 |
ES2374450T3 (es) | 2005-09-20 | 2012-02-16 | OSI Pharmaceuticals, LLC | Marcadores biológicos predictivos de respuesta anticancerígena para inhibidores de cinasa del receptor del factor de crecimiento 1 similar a insulina. |
TW200812615A (en) | 2006-03-22 | 2008-03-16 | Hoffmann La Roche | Tumor therapy with an antibody for vascular endothelial growth factor and an antibody for human epithelial growth factor receptor type 2 |
NZ574580A (en) | 2006-08-21 | 2011-12-22 | Hoffmann La Roche | Her2 tumor therapy with an anti-vegf antibody |
JP2012518657A (ja) | 2009-02-25 | 2012-08-16 | オーエスアイ・ファーマシューティカルズ,エルエルシー | 併用抗癌治療 |
US20110171124A1 (en) | 2009-02-26 | 2011-07-14 | Osi Pharmaceuticals, Inc. | In situ methods for monitoring the EMT status of tumor cells in vivo |
US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099363A1 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
WO2011091550A1 (en) | 2010-01-28 | 2011-08-04 | Bayer Materialscience Ag | High speed dvds |
EP2519826A2 (en) | 2010-03-03 | 2012-11-07 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
AU2011223655A1 (en) | 2010-03-03 | 2012-06-28 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors |
BR112012022506A2 (pt) * | 2010-03-09 | 2017-09-19 | Novus Int Inc | preparação de metionina ou selenometionina a partir de homosserina através de um intermediário de lactona. |
US20120214830A1 (en) | 2011-02-22 | 2012-08-23 | OSI Pharmaceuticals, LLC | Biological markers predictive of anti-cancer response to insulin-like growth factor-1 receptor kinase inhibitors in hepatocellular carcinoma |
WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
US9180185B2 (en) | 2013-01-11 | 2015-11-10 | Hoffman-La Roche Inc. | Combination therapy of anti-HER3 antibodies |
ES2746839T3 (es) | 2014-12-18 | 2020-03-09 | Pfizer | Derivados de pirimidina y triazina y su uso como inhibidores de AXL |
CA3006743A1 (en) | 2015-12-03 | 2017-06-08 | Agios Pharmaceuticals, Inc. | Mat2a inhibitors for treating mtap null cancer |
WO2021155006A1 (en) | 2020-01-31 | 2021-08-05 | Les Laboratoires Servier Sas | Inhibitors of cyclin-dependent kinases and uses thereof |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU3425493A (en) * | 1992-01-16 | 1993-08-03 | Du Pont Merck Pharmaceutical Company, The | Novel neurotransmitter releasers useful for cognition enhancement |
AU686843B2 (en) * | 1994-02-23 | 1998-02-12 | Pfizer Inc. | 4-heterocyclyl-substituted quinazoline derivatives, processes for their preparation and their use as anti-cancer agents |
MX9709867A (es) * | 1995-06-07 | 1998-03-31 | Pfizer | Derivados de pirimidina condensados con un anillo heterociclico, composiciones que contienen los mismos, y uso de los mismos. |
IT1276781B1 (it) * | 1995-06-23 | 1997-11-03 | Gentili Ist Spa | Derivati antrachinonmono- e disolfon- sostituiti e composizioni farmaceutiche che li contengono per il trattamento delle patologie |
EP0760239A3 (en) * | 1995-09-01 | 1999-04-14 | Pfizer Inc. | Therapeutic agents for use in cancer therapy |
AR004010A1 (es) * | 1995-10-11 | 1998-09-30 | Glaxo Group Ltd | Compuestos heterociclicos |
JPH11512750A (ja) * | 1996-06-27 | 1999-11-02 | ファイザー インク. | 2―(2―オキソ―エチリデン)―イミダゾリジン―4―オンの誘導体およびファルネシル蛋白質トランスフェラーゼ阻害物質としてのそれらの使用法 |
-
1998
- 1998-12-09 JP JP10350000A patent/JPH11236333A/ja active Pending
- 1998-12-22 ES ES98310580T patent/ES2191260T3/es not_active Expired - Lifetime
- 1998-12-22 PT PT98310580T patent/PT928788E/pt unknown
- 1998-12-22 DE DE69811329T patent/DE69811329T2/de not_active Expired - Fee Related
- 1998-12-22 DK DK98310580T patent/DK0928788T3/da active
- 1998-12-22 AT AT98310580T patent/ATE232520T1/de not_active IP Right Cessation
- 1998-12-22 EP EP98310580A patent/EP0928788B1/en not_active Expired - Lifetime
- 1998-12-24 CA CA002257016A patent/CA2257016C/en not_active Expired - Fee Related
- 1998-12-28 US US09/221,946 patent/US6080769A/en not_active Expired - Fee Related
- 1998-12-29 BR BR9805734-0A patent/BR9805734A/pt not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
CA2257016C (en) | 2002-06-04 |
EP0928788A1 (en) | 1999-07-14 |
BR9805734A (pt) | 2000-05-16 |
US6080769A (en) | 2000-06-27 |
PT928788E (pt) | 2003-04-30 |
DK0928788T3 (da) | 2003-03-24 |
DE69811329D1 (de) | 2003-03-20 |
CA2257016A1 (en) | 1999-06-30 |
DE69811329T2 (de) | 2003-08-14 |
ATE232520T1 (de) | 2003-02-15 |
EP0928788B1 (en) | 2003-02-12 |
JPH11236333A (ja) | 1999-08-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ES2191260T3 (es) | Derivados de la imidazolidin-4-ona utiles como agentes anticancerosos. | |
PT1029853E (pt) | Derivados biciclicos heteroaromaticos uteis como agentes anticancerigenos | |
TR200201297T2 (tr) | Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2-on türevleri. | |
EA200100135A1 (ru) | Алкинилзамещенные производные хинолин-2-она, полезные в качестве противораковых агентов | |
DE69923849D1 (de) | Quinolin-2-on-derivate verwendbar als antikrebsmittel | |
EA200100553A1 (ru) | Замещенные бициклические производные, полезные в качестве противораковых агентов | |
AP9701039A0 (en) | Derivatives of 2- (2-oxo-ethlidene)-imidazolidin-4-one. | |
TR200003478T2 (tr) | Antikanser maddeleri olarak faydalı izotiyazol türevleri | |
ATE260255T1 (de) | 5-oxo-pyrrolidine-2-carbonsäure- hydroxamidderivate | |
EA200500174A1 (ru) | Новые производные бензимидазола, полезные в качестве антипролиферативных агентов | |
SE9904508D0 (sv) | New compounds | |
EA200100983A1 (ru) | Производные 13-метилэритромицина | |
ES2168581T3 (es) | Derivados de indazol sustituidos. | |
PT992509E (pt) | Novos derivados macrolidos | |
PT916651E (pt) | DERIVADOS DE áCIDO FENILALQUILCARBOXILICO | |
EA200001157A2 (ru) | Новые замещенные производные (дигидро)бензоксазина и (дигидро)бензотиазина, способ их получения и содержащие их фармацевтические композиции | |
PT952157E (pt) | Derivados 9a, 11b-desidro de 9-oxima-3-ceto-6-o-metileritromicina | |
TR200102315T2 (tr) | Antikanser maddeleri olarak faydalı heteroaril-ikame edilmiş kinolin-2- on türevleri. | |
BR9915898A (pt) | Compostos, composição farmacêutica, e, utilização de um composto |